Akt2和Beclin 1在原发性肝癌中的表达及临床意义
|
摘要
目的:通过检测Akt2和Beclin 1在原发性肝癌、肝硬化和正常肝脏组织的表达水平,结合一些临床病理指标,探讨Akt2和Beclin 1的表达水平在原发性肝癌发生发展及转移中的作用及其相互关系。
方法:用RT-PCR和免疫组织化学Elivision法检测76例原发性肝癌组织、54例肝硬化组织和20例正常肝脏组织中的Akt2和Beclin 1的表达水平,结合临床病理指标及其相关性,进行统计学分析。
结果:(1)Akt2主要在肝癌、肝硬化组织中表达,在正常组织中低表达。RT-PCR技术检测76个肝癌组织、54个肝硬化组织,20个正常肝脏组织标本中Akt2 mRNA表达水平。UVIsoft测得肝癌组织、肝硬化组织、正常肝脏组织中Akt2与GAPDH相对灰度值比分别为0.90±0.14、0.19±0.05、0.02±0.02,其差异有统计学意义(F=3.069,P<0.05)。通过免疫组织化学的方法检测Akt2蛋白表达在76例肝癌中阳性率为90.79% (69/76),54例肝硬化组织中阳性率为25.92%(14/54),20例正常肝组织中阳性率为5%(1/20),肝癌组、肝硬化组和正常肝组织组中Akt2表达差异有统计学意义(χ2=82.881,P<0.05)。Akt2的表达与年龄、性别、肿瘤分级、肿瘤大小、HBSAg、AFP值无关(P>0.05),但与肝硬化程度及有无门静脉或胆管癌栓有关(P<0.05)。
(2)Beclin 1主要在肝癌、肝硬化组织中表达,在正常组织中低表达。RT-PCR技术检测76个肝癌组织、54个肝硬化组织,20个正常肝脏组织标本中Beclin 1 mRNA表达水平。UVIsoft测得肝癌组织、肝硬化组织,正常肝脏组织中Beclin 1与GAPDH相对灰度值比分别为0.78±0.10、0.39±0.04、0.04±0.02,其差异有统计学意义(F=5.78,P<0.05)。免疫组织化学的方法检测Beclin 1蛋白表达在76例肝癌中阳性率为84.21% (64/76),54例肝硬化组织中阳性率为37.04%(20/54),20例正常肝组织中阳性率为10%(2/20),肝癌组、肝硬化组和正常肝组织组中Akt2表达差异有统计学意义(χ2=49.85,P<0.05)。原发性肝癌中Beclin 1的表达与年龄、性别、肿瘤分级、肿瘤大小、HBSAg、AFP值及肝硬化程度无关(P>0.05),但与有无门静脉或胆管癌栓有关(P<0.05)。
(3)原发性肝癌中Akt2与Beclin 1成正相关(r=0.947,P=0.04)。
结论:Akt2和Beclin 1在原发性肝癌中高表达,两者相互作用且共同参与原发性肝癌的发生、发展过程,联合检测Akt2和Beclin 1对判断其发生和转移有重要价值,是有潜力的肝癌治疗的候选靶基因。
Objective: To detect Akt2 and Beclin 1 expression in primary hepatic carcinoma (PHC), cirrhotic liver and normal liver tissues, and study their correlations to the clinic pathological features. To explore the effect of Akt2 and Beclin 1 expression in the occurrence,development and metastasis of primary hepatic carcinoma and their interrelation.
Method: The expression of Akt2 and Beclin 1 in 76 cases of primary hepatic carcinoma tissue,54 cases of cirrhotic liver tissue and 20 cases of normal liver tissues were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Elivision immunohistochemistry. The condition of the clinical pathological parameters and their interrelation were analyzed using statistical method.
Result:
1. Akt2 was mainly expressed in primary hepatic carcinoma and cirrhotic liver tissues, there was low expression in normal liver tissues. The Akt2 mRNA expression were 0.90±0.14,0.19±0.05,0.02±0.02 in PHC tissues,cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(F=3.069,P<0.05); The Akt2 protein expression were 90.79%,25.92%, 5% in PHC tissues,cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(χ2=82.881,P<0.05). The expression of Akt2 showed no obvious correlations with the age, gender, Edmondson-steiner grade, tumor size, HBSAg and AFP (P>0.05),but was related to portal vein tumor thrombi and biliary tumor thrombi and the degree of hepatic cirrhosis (P<0.05).
2. Beclin 1 was also mainly expressed in primary hepatic carcinoma and cirrhotic liver tissues and there was low expression in normal liver tissues. The Beclin 1 mRNA expression were 0.78±0.10,0.39±0.04,0.04±0.02 in PHC tissues、cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(F=5.78,P<0.05); The Akt2 protein expression were 84.21%,37.04%,10% in PHC tissues、cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(χ2=49.85, P<0.05). The expression of Beclin 1 showed no obvious correlations with the age, gender, Edmondson-steiner grade, tumor size, HBSAg, AFP and the degree of hepatic cirrhosis (P>0.05),but was related to portal vein tumor thrombi and biliary tumor thrombi (P<0.05).
3. The expression rate of Akt2 was significantly correlated with that of Beclin 1 in primary hepatic carcinoma(r=0.947,P=0.04).
Conclusion: There were higher expression of Akt2 and Beclin 1 in primary hepatic carcinoma. Akt2 and Beclin 1 interact one another and participate in the occurrence、development and metastasis of PHC. Combined detection of Akt2 and Beclin 1 has important value for prediction of occurrence and metastasis. They are both potential target gene for the therapy of PHC.
方法:用RT-PCR和免疫组织化学Elivision法检测76例原发性肝癌组织、54例肝硬化组织和20例正常肝脏组织中的Akt2和Beclin 1的表达水平,结合临床病理指标及其相关性,进行统计学分析。
结果:(1)Akt2主要在肝癌、肝硬化组织中表达,在正常组织中低表达。RT-PCR技术检测76个肝癌组织、54个肝硬化组织,20个正常肝脏组织标本中Akt2 mRNA表达水平。UVIsoft测得肝癌组织、肝硬化组织、正常肝脏组织中Akt2与GAPDH相对灰度值比分别为0.90±0.14、0.19±0.05、0.02±0.02,其差异有统计学意义(F=3.069,P<0.05)。通过免疫组织化学的方法检测Akt2蛋白表达在76例肝癌中阳性率为90.79% (69/76),54例肝硬化组织中阳性率为25.92%(14/54),20例正常肝组织中阳性率为5%(1/20),肝癌组、肝硬化组和正常肝组织组中Akt2表达差异有统计学意义(χ2=82.881,P<0.05)。Akt2的表达与年龄、性别、肿瘤分级、肿瘤大小、HBSAg、AFP值无关(P>0.05),但与肝硬化程度及有无门静脉或胆管癌栓有关(P<0.05)。
(2)Beclin 1主要在肝癌、肝硬化组织中表达,在正常组织中低表达。RT-PCR技术检测76个肝癌组织、54个肝硬化组织,20个正常肝脏组织标本中Beclin 1 mRNA表达水平。UVIsoft测得肝癌组织、肝硬化组织,正常肝脏组织中Beclin 1与GAPDH相对灰度值比分别为0.78±0.10、0.39±0.04、0.04±0.02,其差异有统计学意义(F=5.78,P<0.05)。免疫组织化学的方法检测Beclin 1蛋白表达在76例肝癌中阳性率为84.21% (64/76),54例肝硬化组织中阳性率为37.04%(20/54),20例正常肝组织中阳性率为10%(2/20),肝癌组、肝硬化组和正常肝组织组中Akt2表达差异有统计学意义(χ2=49.85,P<0.05)。原发性肝癌中Beclin 1的表达与年龄、性别、肿瘤分级、肿瘤大小、HBSAg、AFP值及肝硬化程度无关(P>0.05),但与有无门静脉或胆管癌栓有关(P<0.05)。
(3)原发性肝癌中Akt2与Beclin 1成正相关(r=0.947,P=0.04)。
结论:Akt2和Beclin 1在原发性肝癌中高表达,两者相互作用且共同参与原发性肝癌的发生、发展过程,联合检测Akt2和Beclin 1对判断其发生和转移有重要价值,是有潜力的肝癌治疗的候选靶基因。
Objective: To detect Akt2 and Beclin 1 expression in primary hepatic carcinoma (PHC), cirrhotic liver and normal liver tissues, and study their correlations to the clinic pathological features. To explore the effect of Akt2 and Beclin 1 expression in the occurrence,development and metastasis of primary hepatic carcinoma and their interrelation.
Method: The expression of Akt2 and Beclin 1 in 76 cases of primary hepatic carcinoma tissue,54 cases of cirrhotic liver tissue and 20 cases of normal liver tissues were detected by reverse transcription-polymerase chain reaction (RT-PCR) and Elivision immunohistochemistry. The condition of the clinical pathological parameters and their interrelation were analyzed using statistical method.
Result:
1. Akt2 was mainly expressed in primary hepatic carcinoma and cirrhotic liver tissues, there was low expression in normal liver tissues. The Akt2 mRNA expression were 0.90±0.14,0.19±0.05,0.02±0.02 in PHC tissues,cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(F=3.069,P<0.05); The Akt2 protein expression were 90.79%,25.92%, 5% in PHC tissues,cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(χ2=82.881,P<0.05). The expression of Akt2 showed no obvious correlations with the age, gender, Edmondson-steiner grade, tumor size, HBSAg and AFP (P>0.05),but was related to portal vein tumor thrombi and biliary tumor thrombi and the degree of hepatic cirrhosis (P<0.05).
2. Beclin 1 was also mainly expressed in primary hepatic carcinoma and cirrhotic liver tissues and there was low expression in normal liver tissues. The Beclin 1 mRNA expression were 0.78±0.10,0.39±0.04,0.04±0.02 in PHC tissues、cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(F=5.78,P<0.05); The Akt2 protein expression were 84.21%,37.04%,10% in PHC tissues、cirrhotic liver tissues and normal liver tissues, the difference was statistically significant(χ2=49.85, P<0.05). The expression of Beclin 1 showed no obvious correlations with the age, gender, Edmondson-steiner grade, tumor size, HBSAg, AFP and the degree of hepatic cirrhosis (P>0.05),but was related to portal vein tumor thrombi and biliary tumor thrombi (P<0.05).
3. The expression rate of Akt2 was significantly correlated with that of Beclin 1 in primary hepatic carcinoma(r=0.947,P=0.04).
Conclusion: There were higher expression of Akt2 and Beclin 1 in primary hepatic carcinoma. Akt2 and Beclin 1 interact one another and participate in the occurrence、development and metastasis of PHC. Combined detection of Akt2 and Beclin 1 has important value for prediction of occurrence and metastasis. They are both potential target gene for the therapy of PHC.
引文
1. Itamoto T, Nakahara H , Amano H , et al. Repeat hepatectomy for recurrent hepatocellular carcinoma [J] . Surgery, 2007, 141(5):589-597.
2.王志明,周乐杜,吕新生,等.以手术切除为主的综合疗法治疗原发性肝癌:附108例报告[J].中国普通外科杂志,2003,12(9):677-680.
3.杨健,杨超.原发性肝癌术后复发的再治疗[J].江西医药,2008,43(4):300- 302.
4. Sasaki Y, Yemada T, Tanaka H , et al. Risk of recurrence in a long-term follow up after surgery in 417 patients with hepatitis B-or hepatitis C-related hepatocellular carcinoma.[J].Ann Surg.2006, 244(5):771-780.
5. Takada Y, Otsuka M, Todoroki T, et al. Accompanying liver cirrhosis as a risk factor for recurrence after resection of solitary hepatocellular carcinoma[J]. Hepatogastroenterology, 2003, 50(54) :1991-1995.
6. Staal SP. Molecular cloning of the Akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma[J].Proc Natl Acad Sci USA,1987,84(14):5034-5037.
7. Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3- kinase[J].Cell,1995,81(5):727-736.
8. Yuan ZQ, Sun M, Feldman RL, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer [J].Oncogene, 2000, 19(19):2324-2330.
9. Sun M, Wang G, Paciga JE, et al.AKT1/PKB alpha kinase is frequently elevated in human cancer and its constitutive activation is required for oncogenic transformation in NIH3T3 cells[J].Am J Pathol,2001,159(2):431-437.
10. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas[J].J Cell Biochem,2002,87(4):470-476.
11. Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sinbis virusencephalitis by beclin , a novel Bcl-2-interacting protein. J Virol, 1998, 72(11):8586-8596.
12. Futreal PA., Liu Q, Shattuck-Eidens D, et al.BRCA1 mutations in primary breast and ovarian carcinomas. Science, 1994(266):120-122.
13. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation[J ] . Science, 2000, 290 (1):1717-1721.
14. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin1.Nature, 1999, 402(6762):672-676.
15. Kametaka S, Okano T, Ohsumi M, et al. Apg l4p and Apg6/Vps30p form a protein complex essential for antophagy in the yeast, Saccharomyces cerevisiae.J Biol Chem, 1998, 273(35):22284-22291.
16. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin l,a candidate tumor suppressor gene on chromosome 17q21.Genomic, 1999, 59(1):59-65.
17. Koneri K, Goi T, Hirono Y, et al. Beclin 1 gene inhibit s tumor growth in colon cancer cell lines [J ]. Anticancer Res, 2007, 27:1453-1457.
18. Petiot A , OgierDenis E, Blommaart EFC, et al. Distinct classes of phosphatidylinositol 3’-kinases are involved in signaling pathways that control macroautophagy in HT-229 cells. J Biol Chem, 2000, 275 (2):992-998.
19.吴孟超,张柏和.我国肝脏外科现状和发展前景.中华外科杂志,1996 ,34 :515-517.
20. Ohto M, Yoshikawa M, Saisho H, et al. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patient . World J Surg, 1995, 19 :42-46.
21. FujioY, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem, 1999, 274:16349-16354.
22.陈汉,吴孟超,尉公田等. 162例原发性肝癌术后复发再切除的体会.中国现代普通外科进展,1999 ,2 :40-43.
23. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2: 489-501.
24.刘恩宇,易继林,宋炜,李兴睿等.抑癌基因PTEN与pAkt在肝细胞肝癌中表达及其意义.中国医师杂志.2005, 12(7),1585-1587.
25. Xu X, Sakon M, Nagano H, et al.Akt2 expression correlates with prognosis of human hepatocellular carcinoma[J]. Oncol Rep, 2004, 11(1):25-32.
26.林杰,王桂玲,单吉贤.大肠癌组织bFGF, PKB, Cyclin A的表达及其与临床的相关性[J].世界华人消化杂志, 2007, 15(4):370-374.
27.杨鹏,王春友,牛彦锋,等. Akt2、HIF-1a在胰腺癌中的表达及其临床意义[J].中国组织化学与细胞化学杂志, 2006, 15(2):178-181.
28. Yue Z, Jin S, Yang C, et al. Beclin l,an autophagy gene essential for early embryonic development,is a haplonisufficient tumor suppressor. Proc Natl Acad Sci USA,2003,100(25):15077-15082.
29. Liang XH, Yu J, Brown K, et al. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res,2001,61(8):3443-3449.
30.王赞宏,彭芝兰,段振玲等.自噬基因Beclin l在宫颈鳞癌中的表达及其临床意义.四川大学学报(医学版), 2006,37(6):860- 863.
31.康凯夫,王晓蔚,陈小伍,谭光明等. Beclin1在原发性肝细胞癌中的表达及其临床意义.南方医科大学学报. 2009, 29(1):151-153.
32. Gozuaceik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene, 2004, 23(16):2891-2906.
33. Furuya N, Yu J, Byfield M, et al. The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function [J ] . Autophagy, 2005, 1:46-52.
1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2: 489-501.
2. Murthy SS, Tosolini A, Taguchi T, et al. Mapping ofAKT3, encoding a member of the Akt /protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization [J]. Cell Genet, 2000, 88 (1-2): 38-40.
3. Nicholson KM, Anderson NG. The protein kinase B/ Akt signaling pathway in human malignancy. Cell Signal, 2002, 14:381-395.
4. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol, 2003, 3: 426-434.
5. Testa JR, Bellacosa. AKT plays a central role in tumorgenesis[ J ].Proc Natl Acad Sci U S A. 2001, 98 (20) : 10983 - 10985.
6. Liu LX , Liu ZH , Jiang HC , et al . Gene expression profiles of hepatoma cell line HLE. World J Gastroenterol , 2003 , 9 : 683-687.
7. Reif S, Lang A, Lindquist JN, et al. The role focal adhesion kinase-phosphatidyli- nositol 3-kinase-Akt signaling in hepatic stellate cell proliferation and type l collagen expression. J Biol Chem. 2003, 278(10): 8083-8090.
8. Faridi J, Fawcett J, Wang L, et al. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation.Am J Physiol Endocrinol Metab.2003, 285(5):E964-972.
9. Jetzt A, Howe JA, Horn MT, et al. Adenoviralmediated expression of a kinase dead mutant of Akt induces apoptosis selectively intum or cells and suppresses tumor growth in mice [J]. Cancer Res, 2003, 63(20):6697-706.
10. Meier R,Alessi DR,Cron P,et al. Mitogenic activation, phosphorylation and nuclear translocation of protein kinase Beta .J Biol Chem, 1997, 272: 30491- 30497.
11. Nam SY, Jung GA, Hur GC, etal. Upregulation of FLIP(S) by Akt a possible inhibition mechanism of TRAIL induced apoptosis in human gastric cancers [J]. Cancer Sci, 2003, 94(12):1066-1073.
12. Gagnon V, St-Germain ME, Parent S, et al. Akt activity in en-dometrial cancer cells: regulation of cell survival through cIAP21 [J].1nt J Oncol, 2003, 23(3):803-810.
13. Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt implications for cancer therapy[J].Pharmacol Ther, 2002, 93 ( 2 /3 ) :243-251.
14. Qian Y, Corum L, Meng Q, et al. PI3K induced action filament remodeling through Akt and p70S6K1: implication of essential role in cell migration[ J ]. Am J Physiol Cell Physio, 2004, 286 (1):C153-C163.
15. Kim D, Kim S, Koh H, et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production [J].FASE J, 2001, 15 (11) : 1953-1962.
16. Pu P, Kang C, LI J, et al. Antisense and dominant-negative Akt2 cDNA inhibits glioma cell invasion. Tumour Biol.2004, 25(4):172-178.
17. Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines [ J ].Cancer Res, 2003, 63 (9) : 2172-2178.
18. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-2 MMP synthesis and tumor invasion via PI3-2kinase /Akt signaling [J]. Oncogene, 2003, 22 (7): 974-982.
19. Hofseth LJ, Hussain SP, Wogan GN, et al. Nitric oxide in cancer and chemoprevention [J]. Free Radic BiolMed, 2003, 34 (8): 955-968.
20. Dimmler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res, 2000, 86(1):425.
21. Zhong H, Chiles K, Feldser D, et al. Modu1ation of hypoxia inducib1e factor lalpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/ PTEN/ AKT/FRAP path-way in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer ReS, 2000, 60(6):1541-1545.
22. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is 15 constitutively active in non-small cell lung cancer cells and promotesce11ular survival and resistance to chemotherapy and radiation [J].Cancer Res, 2001, 61(10):3986-3997.
23. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF 21.EMBO J, 1996, 15(23):6541-6551.
24. Lin HK, Yeh S, Kang HY, et al. Akt suppresses androgen induced apoptosis by phosphorylating and inhibiting androgenreceptor. Proc Natl Acad Sci USA, 2001, 98(13): 7200-7205.
25. Kang SS, Kwon T, Kwon DY, et al. Akt protein kinase enhances human telomerase activity through phosphorylation oftelomerase reverse transcriptase submit. J Biol Chem,1999, 274(19):13085-13090.
26. Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more[ J] . Int J BiochemCell Biol, 2004, 36(12) : 2405-2419.
27. Klionsky DJ. Autophagy[J] . Curr Biol, 2005, 15(8): 282-283.
28. Jellinger KA, Stadelmann C.Mechanisms of cell death in neurodegenerative disorders. Neural Transm Suppl, 2000, 59:95-114.
29. Cuervo AM. AutoPhagy: in sickness and in health. Trenda Cell Biol, 2004, 14(2):70-77.
30. Toth S, Nagy K, Palfia Z, et al. Cellular autophagic capacity changes during azaserine-induced tumour progression in t he rat pancreas. Up regulation in all premalignant stages and down-regulation with loss of cycloheximide sensitivity of segregation along wit h malignant transformation [J] . Cell Tissue Res, 2002, 309(3): 409-416.
31. Mizushima N, Yamamoto A, Hatano M, et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells[J] . J Cell Biol, 2001, 152 (4): 657-668.
32. Gozuaceik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene, 2004, 23(16):2891-2906.
33. Liang XH, Kleeman LK, Jiang HH,, et al. Protection against fatal Sindbis virus encephalitis by beclin, novel Bcl-2-interaceting protein. J Virol, 1998, 72(11):8586-8596.
34. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science, 1994(266):120-122.
35. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation[J]. Science, 2000, 290 (1):1717-1721.
36. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin1. Nature, 1999, 402(6762):672-676.
37. Kametaka S, Okano T, Ohsumi M, et al. Apg l4p and Apg6/Vps30p form a protein complex essential for antophagy in the yeast. Saccharomyces cerevisiae. J Biol Chem, 1998, 273(35):22284-2229.
38. Tassa A, Roux MP, Attaix D, et al. ClassⅢphosphoinositide 3-kinase-Beclin l complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes. Bio chem J, 2003, 376(Pt 3):577-586.
39. Arico S, Petiot A, Bauvy C, et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol3-kinase /protein kinase B pathway[J] . J Biol Chem, 2001, 276(38) : 35243-35246.
40. Scarlatti F, Bauvy C, Ventruti A, et al. Ceramide-mediated macro autophagy involves inhibition of protein kinase B and up- regulation of beclin 1. J Biol Chem, 2004:279(18):18384-18391.
41. Yu L, Alva A, Su H, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8.Science, 2004, 304(5676):1500-1502.
42. Shimizu S, Kanaseki T, Mizushima N, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol, 2004, 6(12):1221-1228.
43. Koneri K, Goi T , Hirono Y, et al . Beclin 1 gene inhibits tumor growth in colon cancer cell lines [J]. Anticancer Res, 2007, 27:1453-1457.
44. Yue Z, Jin S, Yang C, et al. Beclin l, an autophagy gene essential for early embryonic development, is a haplonisufficient tumor suppressor. Proc Natl Acad Sci USA, 2003, 100(25):15077-15082.
45. Tangir J, Muto MG, Bercowitze RS, et al. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer [J]. Oncogene, 1996 , 12 (4) :735-740.
46. Gao X, Zacharek A, Salkowski A, et al. Loss of heterozygosity of the BRCA1 and other loci on chromo. some 17q in human prostate cancer [J] . Cancer Res, 1995, 55(19):1002-21005.
47. Saito H, Inazawa J, Saito S , et al. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21. 3 often and commonly deleted in tumors[J] . Cancer Res, 1993, 53(14):3382-23385.
48. Liang XH, Yu J, Brown K, et al. Beclin l contains a leucine- rich nuclear report signal that is required for its autophagy and tumor suppresser function. Cancer Res, 2001,61(8):3443- 3449.
49.王赞宏,彭芝兰,段振玲等.自噬基因Beclin l在宫颈鳞癌中的表达及其临床意义.四川大学学报(医学版), 2006;37(6):860- 863.
50. Maiuri MC, Le Toumelin G, Criollo A, et al. Functional and physical interaction between Bcl-2X(L) and a BH3-like domain in Beclin-21 [J ] . Embo J, 2007, 26:2527-2539.
51. Furuya D, Tsuji N, Yagihashi A , et al. Beclin 1 augmented cisdiamminedich -loroplatinum induced apoptosis via enhancing caspase-9 activity [J]. Exp Cell Res, 2005, 307:26-40.
52.王赞宏,彭芝兰,段振玲,闰乃红.自噬基因Beclin 1 shRNA表达质粒的构建及其对宫颈癌细胞HeLa生长的作用. J Sichuan Univ(Med Sci Edi)2007: 38(2):181-185.
53. Mathew R, Kongara S, Beaudoin B, et al. Autophagy suppresses tumor progression by limiting chromosomal instability [J] .Genes Dev, 2007 ,21 :1367-1381.
54. Hawkins CJ, Vaux DL. Analysis of the role of Bcl-2 in apoptosis. Linmunol Rev, 1994;141:127-128.
55. Pattingre S, Levine B, et al. Bcl-2 inhibition of autophagy: a new route to cancer[J]. Cancer Res, 2006, 66 (6) : 2885- 2888.
56. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy[J]. Curr Op in Pharmacol, 2003, 3 (4): 371-377.
2.王志明,周乐杜,吕新生,等.以手术切除为主的综合疗法治疗原发性肝癌:附108例报告[J].中国普通外科杂志,2003,12(9):677-680.
3.杨健,杨超.原发性肝癌术后复发的再治疗[J].江西医药,2008,43(4):300- 302.
4. Sasaki Y, Yemada T, Tanaka H , et al. Risk of recurrence in a long-term follow up after surgery in 417 patients with hepatitis B-or hepatitis C-related hepatocellular carcinoma.[J].Ann Surg.2006, 244(5):771-780.
5. Takada Y, Otsuka M, Todoroki T, et al. Accompanying liver cirrhosis as a risk factor for recurrence after resection of solitary hepatocellular carcinoma[J]. Hepatogastroenterology, 2003, 50(54) :1991-1995.
6. Staal SP. Molecular cloning of the Akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma[J].Proc Natl Acad Sci USA,1987,84(14):5034-5037.
7. Franke TF, Yang SI, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3- kinase[J].Cell,1995,81(5):727-736.
8. Yuan ZQ, Sun M, Feldman RL, et al. Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer [J].Oncogene, 2000, 19(19):2324-2330.
9. Sun M, Wang G, Paciga JE, et al.AKT1/PKB alpha kinase is frequently elevated in human cancer and its constitutive activation is required for oncogenic transformation in NIH3T3 cells[J].Am J Pathol,2001,159(2):431-437.
10. Altomare DA, Tanno S, De Rienzo A, et al. Frequent activation of AKT2 kinase in human pancreatic carcinomas[J].J Cell Biochem,2002,87(4):470-476.
11. Liang XH, Kleeman LK, Jiang HH, et al. Protection against fatal Sinbis virusencephalitis by beclin , a novel Bcl-2-interacting protein. J Virol, 1998, 72(11):8586-8596.
12. Futreal PA., Liu Q, Shattuck-Eidens D, et al.BRCA1 mutations in primary breast and ovarian carcinomas. Science, 1994(266):120-122.
13. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation[J ] . Science, 2000, 290 (1):1717-1721.
14. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin1.Nature, 1999, 402(6762):672-676.
15. Kametaka S, Okano T, Ohsumi M, et al. Apg l4p and Apg6/Vps30p form a protein complex essential for antophagy in the yeast, Saccharomyces cerevisiae.J Biol Chem, 1998, 273(35):22284-22291.
16. Aita VM, Liang XH, Murty VV, et al. Cloning and genomic organization of beclin l,a candidate tumor suppressor gene on chromosome 17q21.Genomic, 1999, 59(1):59-65.
17. Koneri K, Goi T, Hirono Y, et al. Beclin 1 gene inhibit s tumor growth in colon cancer cell lines [J ]. Anticancer Res, 2007, 27:1453-1457.
18. Petiot A , OgierDenis E, Blommaart EFC, et al. Distinct classes of phosphatidylinositol 3’-kinases are involved in signaling pathways that control macroautophagy in HT-229 cells. J Biol Chem, 2000, 275 (2):992-998.
19.吴孟超,张柏和.我国肝脏外科现状和发展前景.中华外科杂志,1996 ,34 :515-517.
20. Ohto M, Yoshikawa M, Saisho H, et al. Nonsurgical treatment of hepatocellular carcinoma in cirrhotic patient . World J Surg, 1995, 19 :42-46.
21. FujioY, Walsh K. Akt mediates cytoprotection of endothelial cells by vascular endothelial growth factor in an anchorage-dependent manner. J Biol Chem, 1999, 274:16349-16354.
22.陈汉,吴孟超,尉公田等. 162例原发性肝癌术后复发再切除的体会.中国现代普通外科进展,1999 ,2 :40-43.
23. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2: 489-501.
24.刘恩宇,易继林,宋炜,李兴睿等.抑癌基因PTEN与pAkt在肝细胞肝癌中表达及其意义.中国医师杂志.2005, 12(7),1585-1587.
25. Xu X, Sakon M, Nagano H, et al.Akt2 expression correlates with prognosis of human hepatocellular carcinoma[J]. Oncol Rep, 2004, 11(1):25-32.
26.林杰,王桂玲,单吉贤.大肠癌组织bFGF, PKB, Cyclin A的表达及其与临床的相关性[J].世界华人消化杂志, 2007, 15(4):370-374.
27.杨鹏,王春友,牛彦锋,等. Akt2、HIF-1a在胰腺癌中的表达及其临床意义[J].中国组织化学与细胞化学杂志, 2006, 15(2):178-181.
28. Yue Z, Jin S, Yang C, et al. Beclin l,an autophagy gene essential for early embryonic development,is a haplonisufficient tumor suppressor. Proc Natl Acad Sci USA,2003,100(25):15077-15082.
29. Liang XH, Yu J, Brown K, et al. Beclin 1 contains a leucine-rich nuclear export signal that is required for its autophagy and tumor suppressor function. Cancer Res,2001,61(8):3443-3449.
30.王赞宏,彭芝兰,段振玲等.自噬基因Beclin l在宫颈鳞癌中的表达及其临床意义.四川大学学报(医学版), 2006,37(6):860- 863.
31.康凯夫,王晓蔚,陈小伍,谭光明等. Beclin1在原发性肝细胞癌中的表达及其临床意义.南方医科大学学报. 2009, 29(1):151-153.
32. Gozuaceik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene, 2004, 23(16):2891-2906.
33. Furuya N, Yu J, Byfield M, et al. The evolutionarily conserved domain of Beclin 1 is required for Vps34 binding, autophagy and tumor suppressor function [J ] . Autophagy, 2005, 1:46-52.
1. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer[J]. Nat Rev Cancer, 2002, 2: 489-501.
2. Murthy SS, Tosolini A, Taguchi T, et al. Mapping ofAKT3, encoding a member of the Akt /protein kinase B family, to human and rodent chromosomes by fluorescence in situ hybridization [J]. Cell Genet, 2000, 88 (1-2): 38-40.
3. Nicholson KM, Anderson NG. The protein kinase B/ Akt signaling pathway in human malignancy. Cell Signal, 2002, 14:381-395.
4. Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents. Curr Opin Pharmacol, 2003, 3: 426-434.
5. Testa JR, Bellacosa. AKT plays a central role in tumorgenesis[ J ].Proc Natl Acad Sci U S A. 2001, 98 (20) : 10983 - 10985.
6. Liu LX , Liu ZH , Jiang HC , et al . Gene expression profiles of hepatoma cell line HLE. World J Gastroenterol , 2003 , 9 : 683-687.
7. Reif S, Lang A, Lindquist JN, et al. The role focal adhesion kinase-phosphatidyli- nositol 3-kinase-Akt signaling in hepatic stellate cell proliferation and type l collagen expression. J Biol Chem. 2003, 278(10): 8083-8090.
8. Faridi J, Fawcett J, Wang L, et al. Akt promotes increased mammalian cell size by stimulating protein synthesis and inhibiting protein degradation.Am J Physiol Endocrinol Metab.2003, 285(5):E964-972.
9. Jetzt A, Howe JA, Horn MT, et al. Adenoviralmediated expression of a kinase dead mutant of Akt induces apoptosis selectively intum or cells and suppresses tumor growth in mice [J]. Cancer Res, 2003, 63(20):6697-706.
10. Meier R,Alessi DR,Cron P,et al. Mitogenic activation, phosphorylation and nuclear translocation of protein kinase Beta .J Biol Chem, 1997, 272: 30491- 30497.
11. Nam SY, Jung GA, Hur GC, etal. Upregulation of FLIP(S) by Akt a possible inhibition mechanism of TRAIL induced apoptosis in human gastric cancers [J]. Cancer Sci, 2003, 94(12):1066-1073.
12. Gagnon V, St-Germain ME, Parent S, et al. Akt activity in en-dometrial cancer cells: regulation of cell survival through cIAP21 [J].1nt J Oncol, 2003, 23(3):803-810.
13. Hill MM, Hemmings BA. Inhibition of protein kinase B/Akt implications for cancer therapy[J].Pharmacol Ther, 2002, 93 ( 2 /3 ) :243-251.
14. Qian Y, Corum L, Meng Q, et al. PI3K induced action filament remodeling through Akt and p70S6K1: implication of essential role in cell migration[ J ]. Am J Physiol Cell Physio, 2004, 286 (1):C153-C163.
15. Kim D, Kim S, Koh H, et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production [J].FASE J, 2001, 15 (11) : 1953-1962.
16. Pu P, Kang C, LI J, et al. Antisense and dominant-negative Akt2 cDNA inhibits glioma cell invasion. Tumour Biol.2004, 25(4):172-178.
17. Grille SJ, Bellacosa A, Upson J, et al. The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines [ J ].Cancer Res, 2003, 63 (9) : 2172-2178.
18. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-2 MMP synthesis and tumor invasion via PI3-2kinase /Akt signaling [J]. Oncogene, 2003, 22 (7): 974-982.
19. Hofseth LJ, Hussain SP, Wogan GN, et al. Nitric oxide in cancer and chemoprevention [J]. Free Radic BiolMed, 2003, 34 (8): 955-968.
20. Dimmler S, Zeiher AM. Akt takes center stage in angiogenesis signaling. Circ Res, 2000, 86(1):425.
21. Zhong H, Chiles K, Feldser D, et al. Modu1ation of hypoxia inducib1e factor lalpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/ PTEN/ AKT/FRAP path-way in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer ReS, 2000, 60(6):1541-1545.
22. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is 15 constitutively active in non-small cell lung cancer cells and promotesce11ular survival and resistance to chemotherapy and radiation [J].Cancer Res, 2001, 61(10):3986-3997.
23. Alessi DR, Andjelkovic M, Caudwell B, et al. Mechanism of activation of protein kinase B by insulin and IGF 21.EMBO J, 1996, 15(23):6541-6551.
24. Lin HK, Yeh S, Kang HY, et al. Akt suppresses androgen induced apoptosis by phosphorylating and inhibiting androgenreceptor. Proc Natl Acad Sci USA, 2001, 98(13): 7200-7205.
25. Kang SS, Kwon T, Kwon DY, et al. Akt protein kinase enhances human telomerase activity through phosphorylation oftelomerase reverse transcriptase submit. J Biol Chem,1999, 274(19):13085-13090.
26. Lockshin RA, Zakeri Z. Apoptosis, autophagy, and more[ J] . Int J BiochemCell Biol, 2004, 36(12) : 2405-2419.
27. Klionsky DJ. Autophagy[J] . Curr Biol, 2005, 15(8): 282-283.
28. Jellinger KA, Stadelmann C.Mechanisms of cell death in neurodegenerative disorders. Neural Transm Suppl, 2000, 59:95-114.
29. Cuervo AM. AutoPhagy: in sickness and in health. Trenda Cell Biol, 2004, 14(2):70-77.
30. Toth S, Nagy K, Palfia Z, et al. Cellular autophagic capacity changes during azaserine-induced tumour progression in t he rat pancreas. Up regulation in all premalignant stages and down-regulation with loss of cycloheximide sensitivity of segregation along wit h malignant transformation [J] . Cell Tissue Res, 2002, 309(3): 409-416.
31. Mizushima N, Yamamoto A, Hatano M, et al. Dissection of autophagosome formation using Apg5-deficient mouse embryonic stem cells[J] . J Cell Biol, 2001, 152 (4): 657-668.
32. Gozuaceik D, Kimchi A. Autophagy as a cell death and tumor suppressor mechanism. Oncogene, 2004, 23(16):2891-2906.
33. Liang XH, Kleeman LK, Jiang HH,, et al. Protection against fatal Sindbis virus encephalitis by beclin, novel Bcl-2-interaceting protein. J Virol, 1998, 72(11):8586-8596.
34. Futreal PA, Liu Q, Shattuck-Eidens D, et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science, 1994(266):120-122.
35. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation[J]. Science, 2000, 290 (1):1717-1721.
36. Liang XH, Jackson S, Seaman M, et al. Induction of autophagy and inhibition of tumorigenesis by beclin1. Nature, 1999, 402(6762):672-676.
37. Kametaka S, Okano T, Ohsumi M, et al. Apg l4p and Apg6/Vps30p form a protein complex essential for antophagy in the yeast. Saccharomyces cerevisiae. J Biol Chem, 1998, 273(35):22284-2229.
38. Tassa A, Roux MP, Attaix D, et al. ClassⅢphosphoinositide 3-kinase-Beclin l complex mediates the amino acid-dependent regulation of autophagy in C2C12 myotubes. Bio chem J, 2003, 376(Pt 3):577-586.
39. Arico S, Petiot A, Bauvy C, et al. The tumor suppressor PTEN positively regulates macroautophagy by inhibiting the phosphatidylinositol3-kinase /protein kinase B pathway[J] . J Biol Chem, 2001, 276(38) : 35243-35246.
40. Scarlatti F, Bauvy C, Ventruti A, et al. Ceramide-mediated macro autophagy involves inhibition of protein kinase B and up- regulation of beclin 1. J Biol Chem, 2004:279(18):18384-18391.
41. Yu L, Alva A, Su H, et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8.Science, 2004, 304(5676):1500-1502.
42. Shimizu S, Kanaseki T, Mizushima N, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol, 2004, 6(12):1221-1228.
43. Koneri K, Goi T , Hirono Y, et al . Beclin 1 gene inhibits tumor growth in colon cancer cell lines [J]. Anticancer Res, 2007, 27:1453-1457.
44. Yue Z, Jin S, Yang C, et al. Beclin l, an autophagy gene essential for early embryonic development, is a haplonisufficient tumor suppressor. Proc Natl Acad Sci USA, 2003, 100(25):15077-15082.
45. Tangir J, Muto MG, Bercowitze RS, et al. A 400 kb novel deletion unit centromeric to the BRCA1 gene in sporadic epithelial ovarian cancer [J]. Oncogene, 1996 , 12 (4) :735-740.
46. Gao X, Zacharek A, Salkowski A, et al. Loss of heterozygosity of the BRCA1 and other loci on chromo. some 17q in human prostate cancer [J] . Cancer Res, 1995, 55(19):1002-21005.
47. Saito H, Inazawa J, Saito S , et al. Detailed deletion mapping of chromosome 17q in ovarian and breast cancers: 2-cM region on 17q21. 3 often and commonly deleted in tumors[J] . Cancer Res, 1993, 53(14):3382-23385.
48. Liang XH, Yu J, Brown K, et al. Beclin l contains a leucine- rich nuclear report signal that is required for its autophagy and tumor suppresser function. Cancer Res, 2001,61(8):3443- 3449.
49.王赞宏,彭芝兰,段振玲等.自噬基因Beclin l在宫颈鳞癌中的表达及其临床意义.四川大学学报(医学版), 2006;37(6):860- 863.
50. Maiuri MC, Le Toumelin G, Criollo A, et al. Functional and physical interaction between Bcl-2X(L) and a BH3-like domain in Beclin-21 [J ] . Embo J, 2007, 26:2527-2539.
51. Furuya D, Tsuji N, Yagihashi A , et al. Beclin 1 augmented cisdiamminedich -loroplatinum induced apoptosis via enhancing caspase-9 activity [J]. Exp Cell Res, 2005, 307:26-40.
52.王赞宏,彭芝兰,段振玲,闰乃红.自噬基因Beclin 1 shRNA表达质粒的构建及其对宫颈癌细胞HeLa生长的作用. J Sichuan Univ(Med Sci Edi)2007: 38(2):181-185.
53. Mathew R, Kongara S, Beaudoin B, et al. Autophagy suppresses tumor progression by limiting chromosomal instability [J] .Genes Dev, 2007 ,21 :1367-1381.
54. Hawkins CJ, Vaux DL. Analysis of the role of Bcl-2 in apoptosis. Linmunol Rev, 1994;141:127-128.
55. Pattingre S, Levine B, et al. Bcl-2 inhibition of autophagy: a new route to cancer[J]. Cancer Res, 2006, 66 (6) : 2885- 2888.
56. Huang S, Houghton PJ. Targeting mTOR signaling for cancer therapy[J]. Curr Op in Pharmacol, 2003, 3 (4): 371-377.